Why This Chapter Exists
Current reality. As of 2026, there is no clinically available blood test, scan, or biomarker that can tell a doctor which root cause of ME/CFS β TRPM3 channelopathy, CNS energy crisis, GPCR autoantibody cascade, or metabolic safe mode lock (Causal Hierarchy: Root Causes, Amplifiers, and Consequences) β is driving a given patientβs illness. Gold-standard tests require lumbar puncture, research-grade flow cytometry, specialized autoantibody panels, or invasive cardiopulmonary exercise testing β none accessible in routine practice.
The logic of medication-as-probe. When a biomarker is unavailable, a medication with a known mechanism of action serves as a functional test: if drug X targets mechanism Y, and the patient improves, mechanism Y was likely dysfunctional. This is the same logic underlying the L-DOPA challenge test in Parkinsonβs disease and the bronchodilator reversibility test in asthma.
What this approach CANNOT do. Medication response cannot distinguish pharmacological effect from placebo. Response cannot distinguish root cause correction from downstream compensation. Non-response is weaker evidence than response β a drug may fail for reasons unrelated to the target mechanism. Most medications discussed lack large ME/CFS-specific RCTs. Combination response patterns multiply individual uncertainties and have never been prospectively validated.
What this approach CAN do. It identifies which physiological systems are likely dysfunctional. It narrows plausible root causes by excluding mechanisms that would have responded to a failed medication. It guides the next treatment step. And it gives patients a framework for understanding their illness β βmy body responds to this, which tells us something about what is happening.β
Certainty. The approach is rational given the diagnostic vacuum, but unvalidated. Every inference should be read with the caveats above in mind. The certainty of each per-medication inference is stated individually. The framework as a whole is Low to Medium β biologically plausible and clinically necessary, but unproven.
Why this matters. This is the chapter patients can hand to their doctors to explain why systematically trying medications, one at a time, with careful monitoring and interpreting the results, is not guesswork. It is diagnostic reasoning under uncertainty, using the tools available in 2026, while we wait for the biomarkers that will eventually make it obsolete.
(Origin: medication-differential-analysis)